Abstract
Medical therapies for hepatocelular carcinoma are limited. Standard antimitotic chemotherapies and hormonotherapies are inefficient. Only sorafenib, an antiangiogenic agent inhibiting the VEGF and PDGF receptors as well as MAP kinase pathway, has shown a significant benefit on patient survival. However, its indication is restricted to patients with multifocal hepatocellular carcinoma not responding to transarterial hepatic chemoembolization or patients with hepatocellular carcinoma invading the venous portal tract or spreading to lymph nodes or as distant visceral metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
